{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:24Z","timestamp":1707524124538},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,16]]},"DOI":"10.7759\/cureus.10482","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T12:24:29Z","timestamp":1600259069000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Challenges with Catastrophic Antiphospholipid Antibody Syndrome: A Case Report"],"prefix":"10.7759","author":[{"given":"Prateek","family":"Harne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parth J","family":"Sampat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneesh","family":"Bisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihad","family":"BenGabr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hom","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis S","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006, 4:295-306. 10.1111\/j.1538-7836.2006.01753.x","journal-title":"J Thromb Haemost"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera R","year":"2002","unstructured":"Cervera R, Piette JC, Font J, et al.. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002, 46:1019-1027. 10.1002\/art.10187","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12860\/jnp.2014.03","article-title":"Catastrophic antiphospholipid syndrome: a clinical review","volume":"3","author":"Nayer A","year":"2014","unstructured":"Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. J Nephropathol. 2014, 3:9-17. 10.12860\/jnp.2014.03","journal-title":"J Nephropathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera R","year":"2014","unstructured":"Cervera R, Rodr\u00edguez-Pint\u00f3 I, Colafrancesco S, et al.. 14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014, 13:699-707. 10.1016\/j.autrev.2014.03.002","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1082266","article-title":"The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making","volume":"34","author":"Asherson RA","year":"2008","unstructured":"Asherson RA. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost. 2008, 34:227-235. 10.1055\/s-0028-1082266","journal-title":"Semin Thromb Hemost"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, et al.. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016, 15:1120-1124. 10.1016\/j.autrev.2016.09.010","journal-title":"Autoimmun Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200111000-00002","article-title":"Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients","volume":"80","author":"Asherson RA","year":"2001","unstructured":"Asherson RA, Cervera R, Piette JC, et al.. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine. 2001, 80:355-377. 10.1097\/00005792-200111000-00002","journal-title":"Medicine"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients","volume":"77","author":"Asherson RA","year":"1998","unstructured":"Asherson RA, Cervera R, Piette JC, et al.. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine. 1998, 77:195-207. 10.1097\/00005792-199805000-00005","journal-title":"Medicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"Bucciarelli S","year":"2006","unstructured":"Bucciarelli S, Espinosa G, Cervera R, et al.. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006, 54:2568-2576. 10.1002\/art.22018","journal-title":"Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5375080","article-title":"Plasma exchange in the management of catastrophic antiphospholipid syndrome","volume":"2016","author":"Titeca-Beauport D","year":"2016","unstructured":"Titeca-Beauport D, Salle V, Kontar L, Maizel J, Choukroun G. Plasma exchange in the management of catastrophic antiphospholipid syndrome. Case Rep Crit Care. 2016, 2016:5375080. 10.1155\/2016\/5375080","journal-title":"Case Rep Crit Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman H","year":"2013","unstructured":"Berman H, Rodr\u00edguez-Pint\u00f3 I, Cervera R, et al.. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013, 12:1085-90. 10.1016\/j.autrev.2013.05.004","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan D","year":"2013","unstructured":"Erkan D, Vega J, Ram\u00f3n G, Kozora E, Lockshin MD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013, 65:464-471. 10.1002\/art.37759","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03491.x","article-title":"Eculizumab","volume":"68","author":"Dubois EA","year":"2009","unstructured":"Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol. 2009, 68:318-319. 10.1111\/j.1365-2125.2009.03491.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key228","article-title":"Eculizumab for catastrophic antiphospholipid syndrome\u2014a case report and literature review","volume":"57","author":"Guillot M","year":"2018","unstructured":"Guillot M, Rafat C, Buob D, et al.. Eculizumab for catastrophic antiphospholipid syndrome\u2014a case report and literature review. Rheumatology. 2018, 57:2055-2057. 10.1093\/rheumatology\/key228","journal-title":"Rheumatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig S","year":"2015","unstructured":"Wig S, Chan M, Thachil J, Bruce I, Barnes T. A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor. Rheumatology. 2015, 55:382-384. 10.1093\/rheumatology\/kev371","journal-title":"Rheumatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos TA","year":"2015","unstructured":"Zikos TA, Sokolove J, Ahuja N, Berube C. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol. 2015, 21:311-313. 10.1097\/RHU.0000000000000290","journal-title":"J Clin Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan M","year":"2014","unstructured":"Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T. 36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014, 2014:1-3. 10.1155\/2014\/704371","journal-title":"Case Rep Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti MG","year":"2019","unstructured":"Tinti MG, Carnevale V, Inglese M, et al.. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019, 19:281-288. 10.1007\/s10238-019-00565-8","journal-title":"Clin Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler A","year":"2014","unstructured":"Kronbichler A, Frank R, Kirschfink M, et al.. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine. 2014, 93:e143. 10.1097\/MD.0000000000000143","journal-title":"Medicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/38344-therapeutic-challenges-with-catastrophic-antiphospholipid-antibody-syndrome-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:39Z","timestamp":1707506559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/38344-therapeutic-challenges-with-catastrophic-antiphospholipid-antibody-syndrome-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.10482","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,16]]}}}